Skip to main navigation

About
Pipeline
Patients
Investors
Contact Us

Investor Relations

Investors
Press Releases
Event Calendar
Stock Info
Governance
Financial Info
Shareholder Services
Presentations

Shareholder Tools

Facebook
LinkedIn
Twitter

Press Releases

Keyword Search

Year

06/05/23

Bellerophon Announces Top-Line Data from Phase 3 REBUILD Clinical Trial of INOpulse® for Treatment of Fibrotic Interstitial Lung Disease

05/15/23

Bellerophon Provides Clinical Program Update and Reports First Quarter 2023 Financial Results

05/11/23

Bellerophon Therapeutics Announces Last Patient Has Completed Blinded Treatment in Phase 3 REBUILD Study for INOpulse® in Fibrotic Interstitial Lung Disease

03/31/23

Bellerophon Provides Clinical Program Update and Reports Full-Year 2022 Financial Results

03/06/23

Bellerophon Therapeutics Announces $5 Million Registered Direct Offering

02/09/23

Bellerophon Therapeutics Receives IND Clearance from China NMPA to Conduct Phase 3 Clinical Trial in China for INOpulse® in Fibrotic Interstitial Lung Disease

01/18/23

Bellerophon Therapeutics Announces Completion of Enrollment in Phase 3 REBUILD Study for INOpulse® in Fibrotic Interstitial Lung Disease

01/05/23

Bellerophon Therapeutics Announces License Agreement for the Commercialization of INOpulse® in Greater China with Baylor BioSciences

© 2023 Bellerophon Therapeutics. All rights reserved.

Site Map
Terms of Use
Privacy Policy